GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Savara Inc (NAS:SVRA) » Definitions » Cyclically Adjusted Price-to-FCF

Savara (Savara) Cyclically Adjusted Price-to-FCF : (As of May. 15, 2024)


View and export this data going back to 1996. Start your Free Trial

What is Savara Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Savara Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Savara's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Savara Cyclically Adjusted Price-to-FCF Chart

Savara Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Savara Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Savara's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Savara's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Savara's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Savara's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Savara's Cyclically Adjusted Price-to-FCF falls into.



Savara Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Savara's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Savara's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.113/129.4194*129.4194
=-0.113

Current CPI (Mar. 2024) = 129.4194.

Savara Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -4.296 100.560 -5.529
201409 -3.064 100.428 -3.949
201412 -2.898 99.070 -3.786
201503 -3.257 99.621 -4.231
201506 -3.693 100.684 -4.747
201509 -3.544 100.392 -4.569
201512 8.264 99.792 10.717
201603 -4.458 100.470 -5.743
201606 7.675 101.688 9.768
201609 -1.059 101.861 -1.346
201612 -0.602 101.863 -0.765
201703 -0.958 102.862 -1.205
201706 -0.556 103.349 -0.696
201709 -0.341 104.136 -0.424
201712 -0.325 104.011 -0.404
201803 -0.309 105.290 -0.380
201806 -0.331 106.317 -0.403
201809 -0.255 106.507 -0.310
201812 -0.294 105.998 -0.359
201903 -0.304 107.251 -0.367
201906 -0.337 108.070 -0.404
201909 -0.274 108.329 -0.327
201912 -0.227 108.420 -0.271
202003 -0.285 108.902 -0.339
202006 -0.132 108.767 -0.157
202009 -0.112 109.815 -0.132
202012 -0.203 109.897 -0.239
202103 -0.125 111.754 -0.145
202106 -0.080 114.631 -0.090
202109 -0.059 115.734 -0.066
202112 -0.061 117.630 -0.067
202203 -0.055 121.301 -0.059
202206 -0.061 125.017 -0.063
202209 -0.053 125.227 -0.055
202212 -0.057 125.222 -0.059
202303 -0.079 127.348 -0.080
202306 -0.069 128.729 -0.069
202309 -0.080 129.860 -0.080
202312 -0.084 129.419 -0.084
202403 -0.113 129.419 -0.113

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Savara  (NAS:SVRA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Savara Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Savara's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Savara (Savara) Business Description

Industry
Traded in Other Exchanges
Address
6836 Bee Cave Road, Building I, Suite 205, Austin, TX, USA, 78746
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Executives
Matthew Pauls director 9 DEER PARK DRIVE, SUITE C, MONMOUTH JUNCTION NJ 08852
David L Lowrance officer: Chief Financial Officer 422 WILLIAM WALLACE DRIVE, FRANKLIN TN 37064
Nevan C Elam director C/O NEKTAR THERAPEUTICS, 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Rick Yang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott D Sandell 10 percent owner
Forest Baskett 10 percent owner
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Paul Edward Walker 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Edward T Mathers 10 percent owner C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878
Growth Equity Opportunities 17, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Raymond Dennis Pratt officer: Chief Medical Officer 208 E CHASE ST, BALTIMORE MD 21202
David A Ramsay director HALOZYME THERAPEUTICS, INC., 11588 SORRENTO VALLEY ROAD, #17, SAN DIEGO CA 92121